FACEBOOK  |  TWITTER  |  INSTAGRAM  |  LINKEDIN  |  Contact Us  |  Site Map
Get Involved

Volunteer to Review Annual Meeting Abstracts


The American Society of Gene & Cell Therapy ASGCT is excited to offer the ability of the gene and cell therapy community to self-nominate or submit recommendations of individuals to review abstracts please complete the form below with the information for the individual you are recommending.

Previous association with ASGCT or attendance at an ASGCT Annual Meeting will be helpful for Abstract Reviewers.

ASGCT Members: log in now to autofill this form if you are volunteering yourself.











Please indicate which ASGCT Abstract Category(ies) you would like to review or would recommend the individual to review.

A. Viral Vector Development
A1. RNA Virus Vectors
A2. AAV Vectors
A3. Adenovirus Vectors and Other DNA Viruses
B. Gene Targeting and Gene Correction
B. Gene Targeting and Gene Correction (involving genome engineering with and without site-specific endonucleases)
C. Oligonucleotide Therapeutics
C. Oligonucleotide Therapeutics (siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
D. Synthetic/Molecular Conjugates and Non-Viral Methods for Delivery of Gene Therapeutics
D. Chemical/Molecular Conjugates and Non-Viral Methods for Delivery of Gene Therapeutics (including exosomes)
E. Disease Models and Clinical Applications (includes inherited and acquired diseases, animal models, and clinical trials)
E1. Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
E2. Cardiovascular and Pulmonary Diseases
E3. Neurologic Diseases (including ophthalmic and auditory diseases)
E4. Musculo-skeletal Diseases
E5. Cancer - Immunotherapy, Cancer Vaccines
E6. Cancer - Oncolytic Viruses
E7. Cancer - Targeted Gene and Cell Therapy
E8. Hematologic and Immunologic Diseases
F. Immunological Aspects of Gene Therapy and Vaccines
F. Immunological Aspects of Gene Therapy (includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines)
G. Cell Therapies (includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)
H. Clinical Translation of Gene and Cell Therapies
H1. Vector and Cell Engineering, Production or Manufacturing
H2. Pharmacology/Toxicology Studies or Assay Development
H3. Clinical Protocol Development, Regulatory Interactions, and Ethics

(If recommending) Please provide some information about the individual including their institution and area of specialty.










Following submission, your nomination will be forwarded to the ASGCT leadership and reviewed.

Timeline
  • October 26, 2016 - Abstract Review forms due for 2017 Annual Meeting.
  • November 20, 2016 - Selections made by ASGCT Abstract Secretary and Abstract Category Chairs.